Literature DB >> 19874397

Characterization and comparison of the properties of sarcoma cell lines in vitro and in vivo.

Joslyn Mills1, Tulio Matos, Elizabeth Charytonowicz, Todd Hricik, Mireia Castillo-Martin, Fabrizio Remotti, Francis Y Lee, Igor Matushansky.   

Abstract

To expand the available tools for investigating human sarcomas, we characterized the primary properties of 22 common, uncommon, and newly characterized sarcoma cell lines representing eight different histological subtypes. Throughout the characterization process we noticed that in vitro markers and assays are poor indicators of tumorigenicity and that generated xenografts often bear little resemblance to the original histopathology. In vitro properties examined included morphology, proliferation rate, cell cycle characteristics, invasiveness, and immunohistochemical expression of p53 and phospho-AKT. In vivo properties examined included days to tumor formation in NOD/SCID mice, xenograft morphology in several locations and immunohistochemical expression of Ki67, p53 and phospho-AKT. We believe that such an in depth comparison of a large cohort of sarcoma cell lines will be useful in both designing and interpreting experiments aimed at elucidating both the molecular biology and efficacy of therapeutic agents in sarcomas. However, that data generated also suggests a small set of sarcoma cell lines may be inappropriate for generalizations regarding biological behavior of specific sarcoma subtypes. Integration of functional genomics or other more sophisticated assays of cell lines may help bridge the differences in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19874397      PMCID: PMC3000410          DOI: 10.1111/j.1749-0774.2009.00073.x

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  17 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Mechanisms of sarcomagenesis.

Authors:  Igor Matushansky; Robert G Maki
Journal:  Hematol Oncol Clin North Am       Date:  2005-06       Impact factor: 3.722

3.  Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines.

Authors:  Takashi Ando; Jiro Ichikawa; Atsushi Okamoto; Kachio Tasaka; Atsuhito Nakao; Yoshiki Hamada
Journal:  J Orthop Res       Date:  2005-04-09       Impact factor: 3.494

4.  Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.

Authors:  Kirsten M Leu; Leo J Ostruszka; Donna Shewach; Mark Zalupski; Vernon Sondak; J Sybil Biermann; Julia Shin-Jung Lee; Carol Couwlier; Krisinda Palazzolo; Laurence H Baker
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

5.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Authors:  Jaap Verweij; Paolo G Casali; John Zalcberg; Axel LeCesne; Peter Reichardt; Jean-Yves Blay; Rolf Issels; Allan van Oosterom; Pancras C W Hogendoorn; Martine Van Glabbeke; Rossella Bertulli; Ian Judson
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

6.  Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas.

Authors:  E Latres; M Drobnjak; D Pollack; M R Oliva; M Ramos; M Karpeh; J M Woodruff; C Cordon-Cardo
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

7.  Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma.

Authors:  M J Heslin; C Cordon-Cardo; J J Lewis; J M Woodruff; M F Brennan
Journal:  Cancer       Date:  1998-08-01       Impact factor: 6.860

8.  p53 Mutation and MDM2 amplification in human soft tissue sarcomas.

Authors:  F S Leach; T Tokino; P Meltzer; M Burrell; J D Oliner; S Smith; D E Hill; D Sidransky; K W Kinzler; B Vogelstein
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

9.  Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway.

Authors:  Igor Matushansky; Eva Hernando; Nicholas D Socci; Joslyn E Mills; Tulio A Matos; Mark A Edgar; Samuel Singer; Robert G Maki; Carlos Cordon-Cardo
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

10.  Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin.

Authors:  H C A Graat; M A Witlox; F H E Schagen; G J L Kaspers; M N Helder; J Bras; G R Schaap; W R Gerritsen; P I J M Wuisman; V W van Beusechem
Journal:  Br J Cancer       Date:  2006-05-30       Impact factor: 7.640

View more
  13 in total

1.  Characterization of a novel radiation-induced sarcoma cell line.

Authors:  Julie Lang; Weizhu Zhu; Brandon Nokes; Grishma Sheth; Petr Novak; Laura Fuchs; George Watts; Bernard Futscher; Neal Mineyev; Alexander Ring; Lauren LeBeau; Ray Nagle; Lee Cranmer
Journal:  J Surg Oncol       Date:  2015-02-02       Impact factor: 3.454

2.  PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma.

Authors:  Elizabeth Charytonowicz; Melissa Terry; Katherine Coakley; Leonid Telis; Fabrizio Remotti; Carlos Cordon-Cardo; Robert N Taub; Igor Matushansky
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

3.  Chromatin structure predicts epigenetic therapy responsiveness in sarcoma.

Authors:  Joslyn Mills; Todd Hricik; Sara Siddiqi; Igor Matushansky
Journal:  Mol Cancer Ther       Date:  2011-01-07       Impact factor: 6.261

4.  Targeting sarcoma tumor-initiating cells through differentiation therapy.

Authors:  Dan Han; Veronica Rodriguez-Bravo; Elizabeth Charytonowicz; Elizabeth Demicco; Josep Domingo-Domenech; Robert G Maki; Carlos Cordon-Cardo
Journal:  Stem Cell Res       Date:  2017-04-13       Impact factor: 2.020

5.  Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.

Authors:  Sandhya Noronha; Lauren A C Alt; Taylor E Scimeca; Omran Zarou; Justyna Obrzut; Brian Zanotti; Elizabeth A Hayward; Akhil Pillai; Shubha Mathur; Joseph Rojas; Ribhi Salamah; Nalini Chandar; Michael J Fay
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-12-01       Impact factor: 2.416

6.  Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming.

Authors:  X Zhang; F D Cruz; M Terry; F Remotti; I Matushansky
Journal:  Oncogene       Date:  2012-07-09       Impact factor: 9.867

7.  Hiwi mediated tumorigenesis is associated with DNA hypermethylation.

Authors:  Sara Siddiqi; Melissa Terry; Igor Matushansky
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

8.  Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line.

Authors:  Joseph B Moore; David M Loeb; Kyung U Hong; Poul H Sorensen; Timothy J Triche; David W Lee; Michael I Barbato; Robert J Arceci
Journal:  Front Cell Dev Biol       Date:  2015-03-09

9.  Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model.

Authors:  S Rudnick-Glick; E Corem-Salkmon; I Grinberg; S Margel
Journal:  J Nanobiotechnology       Date:  2016-12-05       Impact factor: 10.435

10.  Characterization of liposarcoma cell lines for preclinical and biological studies.

Authors:  Eva W Stratford; Russell Castro; Jeanette Daffinrud; Magne Skårn; Silje Lauvrak; Else Munthe; Ola Myklebost
Journal:  Sarcoma       Date:  2012-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.